[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infertility-unexplained\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infertility-unexplained":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,71,108,140,167,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100624079","biological-aging-hallmarks-guided-integrative-tcm-and-conventional-medicine-in-post-treatment-unexplained-female-infertility-100624079",false,"NCT07404969","Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility","An Interventional Study Evaluating Telomere and Biological Aging Hallmarks Profiling to Guide an Integrative Traditional Chinese and Conventional Medicine Approach in Women With Post-Treatment Unexplained Infertility","TECMI","Inclusion Criteria:\n\n* Biological female participants aged 25 to 42 years.\n* Diagnosis of infertility defined as failure to conceive after at least 12 months of unprotected intercourse and\u002For repeated failure of assisted reproductive technologies (ART), including intrauterine insemination (IUI) and\u002For in vitro fertilization (IVF).\n* History of post-treatment unexplained or functionally idiopathic infertility, defined as persistent infertility despite adequate correction or management of identifiable reproductive conditions (e.g., endometriosis, polycystic ovary syndrome, hormonal imbalance, uterine factors).\n* Eligibility for natural conception attempts and\u002For assisted reproductive technologies according to routine clinical practice.\n* Willingness to undergo biological aging biomarker profiling, including leukocyte telomere analysis.\n* Ability and willingness to comply with study procedures, including the preconception integrative intervention and follow-up assessments.\n* Provision of written informed consent prior to participation.\n\nExclusion Criteria:\n\n* Current pregnancy or breastfeeding at the time of enrollment.\n* Known chromosomal abnormalities or genetic conditions directly impairing fertility (e.g., Turner syndrome).\n* Untreated severe male factor infertility precluding conception by natural or standard ART methods.\n* Active malignancy or history of cancer requiring systemic treatment within the past 5 years.\n* Severe systemic disease or medical condition contraindicating pregnancy or participation in ART (as determined by the treating physician).\n* Use of investigational drugs or participation in another interventional clinical trial that could interfere with the study outcomes.\n* Known hypersensitivity or contraindication to components of the integrative intervention, as determined by clinical assessment.\n* Any condition which, in the opinion of the investigator, would interfere with safe participation or interpretation of study results.","FEMALE","25 Years","42 Years",{"count":21,"type":22},15,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to determine whether telomere profiling and other biological aging hallmarks can help identify underlying mechanisms of persistent infertility in women with post-treatment unexplained infertility. The study also evaluates whether a personalized integrative treatment guided by these biomarkers can improve reproductive outcomes.\n\nThe study includes women aged 25 to 42 years who continue to experience infertility despite appropriate management of identifiable reproductive conditions and repeated attempts with assisted reproductive technologies (ART), such as intrauterine insemination (IUI) or in vitro fertilization (IVF).\n\nThe main questions this study aims to answer are:\n\n* Can telomere and biological aging hallmarks profiling identify a biological aging phenotype associated with infertility?\n* Can an integrative treatment guided by these profiles improve clinical pregnancy outcomes?\n\nParticipants will:\n\n* Undergo a baseline reproductive evaluation and blood-based assessment of telomeres and aging hallmarks.\n* Receive an integrative approach combining Traditional Chinese Medicine (TCM), targeted nutritional support, and standard fertility care.\n* Proceed with natural conception attempts or standard assisted reproductive technologies following the preconception phase.\n* Participants will be followed to assess pregnancy outcomes and changes in biological aging hallmarks.",[28,29,30,31,32],"Idiopathic Infertility","Infertility Unexplained","Infertility (IVF Patients)","Infertility Assisted Reproductive Technology","Infertility Female",[34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57],"Telomere dysfunction","Telomere attrition","Telomere biology","Cellular aging","Mitochondrial dysfunction","Cellular senescence","Reproductive aging","Functional infertility","Idiopathic infertility","Post-treatment unexplained infertility","Oocyte quality","Endometrial receptivity","Biomarkers of reproductive quality","Single-cell FISH","Leukocyte telomere length","Molecular etiology of infertility","Aging hallmarks","Traditional Chinese Medicine","Integrative fertility therapy","Nutraceutical support","Mitochondrial biogenesis","Oxidative stress","Reproductive resilience","Beyond Genomix","RECRUITING","2026-04-28",{"date":61,"type":62},"2026-04-29","ACTUAL",{"date":64,"type":62},"2025-01-01",{"date":66,"type":22},"2026-12-01",{"name":68,"class":69},"BEYOND GENOMiX SA, AG, Ltd","INDUSTRY",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":70},"100445448","phase-4-luteal-phase-support-in-iui-moh-treatment-luteal-phase-support-in-iui-moh-treatment-100445448","NCT05080569","Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment","LUMO Study: Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH","LUMO","Inclusion Criteria:\n\n* Couples starting IUI with Mild Ovarian HyperStimulation (MOH), with the intend to receive this treatment for at least six months.\n* Diagnosis of unexplained (primary or secondary) infertility\n* Hunault \\\u003C30% (or \\>30%, after an expectant management period of at least 6 additional months).\n* Females aged \\>18 years with regular menstrual cycle.\n* Total mobile sperm count (VCM) \\>10 million.\n\nExclusion cirteria:\n\n* Cycle irregularities\n* Male factor infertility","18 Years",{"count":81,"type":22},1008,[83],"PHASE4","The LUMO study is a multicenter, randomized controlled trial that evaluates the effectivity of luteal phase support in MOH\u002FIUI treatment.",[86,87,88,29],"Pregnancy Related","Fertility Issues","Luteal Phase Defect",[90,91,92,93,94,95,96,97],"progesterone","Cost-effective","Intrauterine insemination","live birth","luteal support","ongoing pregnancy","ovulation induction","unexplained infertility","2025-12-23",{"date":100,"type":62},"2025-12-31",{"date":102,"type":62},"2023-03-01",{"date":104,"type":22},"2027-07",{"name":106,"class":107},"UMC Utrecht","OTHER",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":121,"conditions":122,"keywords":125,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100610668","phase-2-autologous-decidual-like-natural-killer-cells-therapy-for-reproductive-failure-100610668","NCT07230574","Autologous Decidual-like Natural Killer Cells Therapy for Reproductive Failure","A Prospective, Multicenter, Randomized Controlled Clinical Study on Autologous Decidual-like NK Cells Therapy for Reproductive Failure Associated With Abnormal Uterine Natural Killer Cells","Inclusion Criteria:\n\n* Reproductive failure with abnormal endometrial natural killer (NK) cells in menstrual blood;\n* With a clear intention to conceive;\n* Normal ovarian function, or premature ovarian insufficiency with ≥2 high-quality cryopreserved embryos available for transfer;\n* Endometrial thickness measured by transvaginal ultrasound during the periovulatory period ≥7 mm;\n* Body mass index (BMI) between 18 kg\u002Fm² and 28 kg\u002Fm²;\n* Willing to comply with the follow-up plan of this study.\n\nExclusion Criteria:\n\n* Use of progesterone receptor modulators;\n* One of the couple's chromosomal karyotype abnormalities, with no euploid embryo identified via preimplantation genetic testing for aneuploidy;\n* Severe endometriosis or adenomyosis, uterine fibroids affecting uterine cavity morphology, uterine malformations, intrauterine adhesions, or thin endometrium;\n* Uncontrolled autoimmune or endocrine disorders;\n* Contraindications to pregnancy;\n* History of malignant tumors;\n* Participating in other clinical studies;\n* Allergy to blood products.","22 Years","38 Years",{"count":118,"type":22},159,[120],"PHASE2","The aim of this study is to verify the efficacy of in vitro induction of autologous decidual-like NK cells therapy for reproductive failure associated with uterine NK cells abnormalities.",[123,29,124],"Abortion, Missed","Reproductive Disorder",[126,127,128,129],"Recurrent Pregnancy Loss","Repeated Implantation Failure","Unexplained Infertility","Decidual Natural Killer Cells","NOT_YET_RECRUITING","2025-11-13",{"date":133,"type":62},"2025-11-17",{"date":135,"type":22},"2025-11",{"date":137,"type":22},"2028-09",{"name":139,"class":107},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":70},"100579237","phase-1-autologous-decidual-like-natural-killer-cells-therapy-for-infertility-or-adverse-pregnancy-history-100579237","NCT06821685","Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History","Clinical Study of Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History Caused by Abnormal Uterine Natural Killer Cells","Inclusion Criteria:\n\n* abnormal uterine NK cell function;\n* have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two IVF cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction;\n* have clear fertility desires;\n* normal ovarian function or with frozen embryos;\n* edometrium thickness measured by vaginal ultrasound before ovulation or at mid-luteal phase \\>= 7mm;\n* 18kg\u002Fm\\^2 \\\u003C Body mass index \\\u003C 30kg\u002Fm\\^2;\n\nExclusion Criteria:\n\n* using progesterone receptor modulator;\n* chromosomal karyotype abnormalities in one spouse;\n* severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium;\n* uncontrolled autoimmune diseases;\n* abnormal blood coagulation function, abnormal liver and kidney function, or other uncontrolled basic diseases (hypertension, diabetes, thyroid disease, etc.) that the researcher access which may affect the progress of the study;\n* history of pelvic malignant tumors;\n* currently participating in other clinical studies;\n* allergic to blood products.","40 Years",{"count":149,"type":22},14,[151],"PHASE1","The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.",[154,29,155,156],"Abortion, Habitual","Embryo Implantation","Pre-Eclampsia",[158,159,97,160],"recurrent pregnancy loss","repeated implantation failure","decidual natural killer cells",{"date":133,"type":62},{"date":163,"type":62},"2025-02-13",{"date":165,"type":22},"2027-12",{"name":139,"class":107},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":174,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":70},"100502635","endometriosis-and-peritoneal-dysbiosis-100502635","NCT05824819","Endometriosis and Peritoneal Dysbiosis","\"Is the Reduced Quality of Life of Women With Endometriosis the Result of Peritoneal Dysbiosis?\"","Inclusion Criteria:\n\n* age 18-45 years\n* indications for surgical treatment of endometriosis by laparoscopy and\u002For indications for invasive diagnostics by laparoscopy due to idiopathic infertility.\n\nExclusion Criteria:\n\n* abdominal surgeries performed within 6 months prior hospitalisation\n* active infection of the genital tract\n* inflammatory bowel disease\n* antibiotic therapy and use of probiotics within 3 months before surgery","45 Years",{"count":176,"type":22},100,[25],"Endometriosis is a complex clinical syndrome that impairs many aspects of a woman's life, characterized by a chronic estrogen-dependent inflammatory process, mainly affecting the pelvic organs, with ectopic presence of tissue analogous to the uterine mucosa (endometrium). Despite intensive research in the field of etiopathogenesis, its cause has not yet been determined, and treatment remains symptomatic. Endometriosis causes two main complications, i.e. pelvic pain syndrome and infertility. In recent years, thanks to the analysis of the human microbiome, it has become possible to deepen the knowledge of the physiological and pathological interactions between microorganisms inhabiting various body areas and the host. Bacteria may enter the peritoneal cavity in the mechanism of retrograde menstruation and translocate from the intestines, and then promote the development of local and systemic inflammation, leading to the symptoms of endometriosis. The study is to determine whether the presence of a specific intestinal, peritoneal and uterine microbiome correlates with endometriosis stage and whether its presence predisposes to increased pain or infertility. Concordance or divergence of bacterial populations inhabiting the peritoneal and uterine cavities could have clinical implications, i.e. the possibility of empirical antibiotic therapy in patients undergoing only endometrial aspiration biopsy and not opting for surgical treatment.",[180,29],"Endometriosis","2025-04-13",{"date":183,"type":62},"2025-04-15",{"date":185,"type":62},"2023-05-01",{"date":187,"type":22},"2025-12-30",{"name":189,"class":107},"Jagiellonian University",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":198,"minAge":79,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},"100557514","aftificial-inteligence-in-assisted-reproductive-techniques-to-assess-oocyte-quality-and-embryo-ploidy-100557514","NCT06539104","Aftificial Inteligence in Assisted Reproductive Techniques to Assess Oocyte Quality and Embryo Ploidy","Scanning the Meiotic Spindle in Assisted Reproductive Techniques to Assess Oocyte Quality and Embryo Ploidy Evaluated by Artificial Intelligence (SMARTAI Study)","SMARTAI","Inclusion Criteria:\n\n* Intracytoplasmatic Sperm Injection\n* Preimplantation genetic testing\n* Time lapse embryo record\n* Singned informed consent\n\nExclusion Criteria:\n\n* Gynecological diseases\n* Genetical diseases of parents","ALL","49 Years",{"count":201,"type":22},1000,"OBSERVATIONAL","The assisted reproduction success rate is affected by several factors including the age of the women, oocyte quality and maturation state, as well as sperm quality. Imaging of the meiotic spindle may be crucial for determining the oocyte maturation. Artificial intelligence (AI) will be applied to establish the complex oocyte quality, embryo ploidy and pregnancy success probability from the sequence of data, starting with the recording of the meiotic spindle in polarized light, through paternal factors up to the time lapse recording of early embryo development. This strategy should reduce the cost of fertility treatment thanks to increased efficiency in choosing the most promising candidates and reducing the need for costly laboratory analyses.",[205,206,207,29],"Infertility","Infertility, Female","Infertility, Male",[209,210,211,212,213,214,215],"infertility","humant oocyte","IVF","arteficial inteligence","Sperm count","meiotic spindle","time lapse","2025-01-17",{"date":218,"type":62},"2025-01-22",{"date":220,"type":62},"2024-01-05",{"date":222,"type":22},"2028-03-31",{"name":224,"class":107},"Charles University, Czech Republic",4]